Anaheim, CA -- (ReleaseWire) -- 05/03/2017 --BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on Fox & Friends, this morning to discuss the naltrexone implant and BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders that BioCorRx is developing.
Fox & Friends is a daily morning news/talk program airing on Fox News Channel hosted by Steve Doocy, Brian Kilmeade, and Ainsley Earhardt. It begins at 6:00 a.m. Eastern Time with the latest Fox News Live headlines and news of the morning and continues with a variety of segments including current events, interviews, updates of news stories with correspondents, political analysis from the hosts, and entertainment segments.
The segment can be viewed online at: http://video.foxnews.com/v/5420213661001/?playlist_id=930909787001#sp=show-clips.
BioCorRx Inc. (OTCMKTS:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s).
For more information on BICX, visit http://www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Crescendo Communications, LLC
Source: Uptick Newswire